Jump to content

Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes: [[:Category:Biologics|Biologic]]

& routes

: Subcutaneous

or Subcutaneous (abdomen

Use the filters below to narrow your results.

Adalimumab (1) · Evolocumab (1)

Humira; biosimilars Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yusimry, Abrilada (1) · Repatha (1)

None (1) · '"`UNIQ--vote-000010F8-QINU`"' Pre-treatment screening for latent TB (PPD or IGRA) and chronic hepatitis B is standard. Anti-drug antibody formation is a recognized cause of secondary loss of response'"`UNIQ--ref-000010F9-QINU`"'. (1)

None (1) · '"`UNIQ--vote-0000147C-QINU`"', '"`UNIQ--vote-0000147D-QINU`"', '"`UNIQ--vote-0000147E-QINU`"' (1)

140 mg SC every 2 weeks OR 420 mg SC monthly (3 consecutive injections 5 minutes apart due to volume) (1) · 40 mg SC every other week (most adult indications); IBD induction 160 mg week 0, 80 mg week 2, then 40 mg every other week (1)

140 mg/mL single-use prefilled syringe and SureClick autoinjector; Pushtronex 420 mg/3.5 mL on-body infusor (1) · 40 mg/0.4 mL or 40 mg/0.8 mL prefilled syringe and autoinjector pen; 10, 20, 80 mg pediatric/induction strengths (1)

40 mg every week (selected indications); otherwise 40 mg every other week (1) · 420 mg/month (1)

LDL reduction ~50-60% from baseline at 1-2 weeks (1) · Symptomatic effect within weeks; full response by 12-24 weeks (1)

2 weeks per dose (1) · 2-4 weeks per dose (1)

~11-17 days'"`UNIQ--ref-0000147F-QINU`"' (1) · ~14 days'"`UNIQ--ref-00001103-QINU`"' (1)

~64% from SC depot'"`UNIQ--ref-00001104-QINU`"' (1) · ~72% from SC depot'"`UNIQ--ref-00001480-QINU`"' (1)

None (1) · Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

None (1) · [[USLegal:Prescription only|Rx-only]] in US (1)

Showing below up to 2 results in range #1 to #2.

A

Adalimumab

E

Evolocumab

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"